Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue

Journal of Liposome Research

Volumn 24, Issue 3, 2014, Pages 182-190

  Zhaorigetu, Siqin ^a,b   Rodriguez Aguayo, Cristian ^b,c   Sood, Anil K ^b,c,d   Lopez Berestein, Gabriel ^b,c   Walton, Brian L ^a,b,c  

^a TEXAS HEART INSTITUTE   (United States)

^b Department of Experimental Therapeutics ^*  (United States)

^c Center for RNA Interference and Non Coding RNA   (United States)

^d UNIVERSITY OF TEXAS   (United States)

Author keywords

Atherosclerosis; Endocytosis; Human coronary artery endothelial cells; Macrophage

Indexed keywords

AMANTADINE; APOLIPOPROTEIN E; CLATHRIN; LIPOSOME; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; ANION; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; CELL DEATH; CELL STIMULATION; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORONARY ARTERY; ENDOCYTOSIS; ENDOTHELIUM CELL; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; INFLAMMATION; LIPOSOMAL DELIVERY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSMISSION ELECTRON MICROSCOPY; ANIMAL; AORTA; BIOSYNTHESIS; DEFICIENCY; DRUG EFFECTS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

AMANTADINE; ANIMALS; ANIONS; AORTA; APOLIPOPROTEINS E; CLATHRIN; ENDOCYTOSIS; ENDOTHELIUM, VASCULAR; HUMANS; LIPOSOMES; MACROPHAGES; MICE; PLAQUE, ATHEROSCLEROTIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84906226774     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.3109/08982104.2013.863208     Document Type: Article

References (46)

1. Bhargava P, Lee CH. (2012). Role and function of macrophages in the metabolic syndrome. Biochem J 442:253-62.
2. Breslow JL. (1996). Mouse models of atherosclerosis. Science 272: 685-8.
3. Brodsky FM, Chen CY, Knuehl C, et al. (2001). Biological basket weaving: formation and function of clathrin-coated vesicles. Annu Rev Cell Dev Biol 17:517-68.
4. Chang DK, Chiu CY, Kuo SY, et al. (2009). Antiangiogenic targeting liposomes increase therapeutic efficacy for solid tumors. J Biol Chem 284:12905-16.
5. Eckels PC, Banerjee A, Moore EE, et al. (2009). Amantadine inhibits platelet-activating factor induced clathrin-mediated endocytosis in human neutrophils. Am J Physiol Cell Physiol 297:C886-97.
6. Feig JE, Feig JL. (2012). Macrophages, dendritic cells, and regression of atherosclerosis. Front Physiol 3:286.
7. Filion MC, Phillips NC. (1997). Toxicity and immunomodulatory activity of liposomal vectors formulated with cationic lipids toward immune effector cells. Biochim Biophys Acta 1329:345-56.
8. Fuster V, Fayad ZA, Moreno PR, et al. (2005). Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol 46: 1209-18.
9. Gawaz M, Langer H, May AE. (2005). Platelets in inflammation and atherogenesis. J Clin Invest 115:3378-84.
10. Granada JF, Kaluza GL, Raizner AE, Moreno PR. (2004). Vulnerable plaque paradigm: prediction of future clinical events based on a morphological definition. Catheter Cardiovasc Interv 62:364-74.
11. Hamilton AJ, Huang SL, Warnick D, et al. (2004). Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol 43:453-60.
12. Hansson GK, Libby P. (2006). The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 6:508-19.
13. Jawien J. (2012). The role of an experimental model of atherosclerosis: apoE-knockout mice in developing new drugs against atherogenesis. Curr Pharm Biotechnol 13:2435-9.
14. Jefferson BK, Topol EJ. (2005). Molecular mechanisms of myocardial infarction. Curr Probl Cardiol 30:333-74.
15. Kisseleva T, Song L, Vorontchikhina M, et al. (2006). NF-kappaB regulation of endothelial cell function during LPS-induced toxemia and cancer. J Clin Invest 116:2955-63.
16. Landen Jr CN, Chavez-Reyes A, Bucana C, et al. (2005). Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65:6910-18.
17. Libby P. (2001). Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 104:365-72.
18. Libby P. (2002). Inflammation in atherosclerosis. Nature 420:868-74.
19. Lonez C, Vandenbranden M, Elouahabi A, Ruysschaert JM. (2008). Cationic lipid/DNA complexes induce TNF-alpha secretion in splenic macrophages. Eur J Pharm Biopharm 69:817-23.
20. Lopez-Berestein G. (1987). Liposomes as carriers of antimicrobial agents. Antimicrob Agents Chemother 31:675-8.
21. Lopez-Berestein G. (1989). Liposomes in infectious diseases: present and future. Curr Clin Top Infect Dis 10:241-53.
22. Lopez-Berestein G, Kasi L, Rosenblum MG, et al. (1984a). Clinical pharmacology of 99mTc-labeled liposomes in patients with cancer. Cancer Res 44:375-8.
23. Lopez-Berestein G, Rosenblum MG, Mehta R. (1984b). Altered tissue distribution of amphotericin B by liposomal encapsulation: comparison of normal mice to mice infected with Candida albicans. Cancer Drug Deliv 1:199-205.
24. Luttrell LM, Ferguson SS, Daaka Y, et al. (1999). Beta-arrestindependent formation of beta2 adrenergic receptor-Src protein kinase complexes. Science 283:655-61.
25. Mangala LS, Zuzel V, Schmandt R, et al. (2009). Therapeutic targeting of ATP7B in ovarian carcinoma. Clin Cancer Res 15:3770-80.
26. Mcmahon HT, Boucrot E. (2011). Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 12:517-33.
27. Mellman I. (1996). Endocytosis and molecular sorting. Annu Rev Cell Dev Biol 12:575-625.
28. Naghavi M, Libby P, Falk E, et al. (2003). From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation 108:1772-8.
29. Nakashima Y, Plump AS, Raines EW, et al. (1994). ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb 14:133-40.
30. Parthasarathy S, Printz DJ, Boyd D, et al. (1986). Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Arteriosclerosis 6:505-10.
31. Pelkmans L, Helenius A. (2002). Endocytosis via caveolae. Traffic 3: 311-20.
32. Piedrahita JA, Zhang SH, Hagaman JR, et al. (1992). Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 89:4471-5.
33. Plump AS, Smith JD, Hayek T, et al. (1992). Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343-53.
34. Quinn MT, Parthasarathy S, Fong LG, Steinberg D. (1987). Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc Natl Acad Sci USA 84:2995-8.
35. Ross R. (1993). The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362:801-9.
36. Ross R. (1999a). Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-26.
37. Ross R. (1999b). Atherosclerosis is an inflammatory disease. Am Heart J 138:S419-20.
38. Salmon AH, Neal CR, Sage LM, et al. (2009). Angiopoietin-1 alters microvascular permeability coefficients in vivo via modification of endothelial glycocalyx. Cardiovasc Res 83:24-33.
39. Sluimer JC, Kolodgie FD, Bijnens AP, et al. (2009). Thin-walled microvessels in human coronary atherosclerotic plaques show incomplete endothelial junctions relevance of compromised structural integrity for intraplaque microvascular leakage. J Am Coll Cardiol 53:1517-27.
40. Stocker R, Keaney Jr JF. (2004). Role of oxidative modifications in atherosclerosis. Physiol Rev 84:1381-478.
41. Walton BL, Leja M, Vickers KC, et al. (2010). Delivery of negatively charged liposomes into the atheromas of Watanabe heritable hyperlipidemic rabbits. Vasc Med 15:307-13.
42. Wang JC, Bennett M. (2012). Aging and atherosclerosis: mechanisms, functional consequences, and potential therapeutics for cellular senescence. Circ Res 111:245-59.
43. Weber C, Zernecke A, Libby P. (2008). The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 8:802-15.
44. Yusuf S, Reddy S, Ounpuu S, Anand S. (2001). Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circulation 104:2855-64.
45. Zaragoza C, Gomez-Guerrero C, Martin-Ventura JL, et al. (2011). Animal models of cardiovascular diseases. J Biomed Biotechnol 2011: 497841 (1-13).
46. Zhang SH, Reddick RL, Piedrahita JA, Maeda N. (1992). Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468-71.